FDA broadens label for Amgen's Uplizna as it enters rare disease competition
FDA broadens label for Amgen's Uplizna as it enters rare disease competition
Contenido no disponible. Consulta la fuente original.
FDA broadens label for Amgen's Uplizna as it enters rare disease competition
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.